Keyphrases
Treatment Outcome
100%
Germline mutation
100%
BRCA1, BRCA2
100%
Pathogenic Variants
100%
Breast Radiation
100%
Multigene Panel Testing
100%
Radiation Therapy
60%
Overall Survival
40%
Locoregional Recurrence
40%
Patients with Breast Cancer
40%
Adjuvant Radiation Therapy
40%
Disease-specific Mortality
40%
Oncological Outcomes
40%
Cancer Center
20%
Tumor Protein p53 (TP53)
20%
Breast Cancer
20%
Confidence Interval
20%
Standard of Care
20%
Screening Program
20%
Recurrent Disease
20%
BRCA2
20%
In(III)
20%
Locoregional Disease
20%
Follow-up Time
20%
Breast Cancer Susceptibility Gene 1 (BRCA1)
20%
Clinical Stage I
20%
Diverse Populations
20%
PALB2
20%
Late Toxicity
20%
Genetic Screening
20%
3-group
20%
CHEK2
20%
Between-group
20%
Acute Toxicity
20%
Mutated Genes
20%
Toxicity Outcomes
20%
Radiation Toxicity
20%
CDH1
20%
Multigene
20%
Breast Wall
20%
Elective Nodal Irradiation
20%
Panel Testing
20%
Genetic Panel
20%
Chest Wall Radiation
20%
Panel Evaluation
20%
Medicine and Dentistry
BRCA1
100%
Germline Mutation
100%
Radiation Therapy
83%
Breast Cancer
50%
Recurrent Disease
33%
Overall Survival
33%
Malignant Neoplasm
16%
Diseases
16%
Clinical Stage
16%
Screening
16%
BRCA2
16%
Thoracic Wall
16%
Genetic Screening
16%
Breast Surgery
16%
Biochemistry, Genetics and Molecular Biology
BRCA1
100%
Germline Mutation
100%
Overall Survival
33%
Genetics
16%
Screening
16%
BRCA2
16%
PALB2
16%
Genetic Screening
16%
CHEK2
16%
Mutated Genes
16%